01 Stock Market
U.S. stock futures were little changed Friday as traders came back from the Christmas holiday, with the major averages on pace for weekly gains.
Dow Jones Industrial Average futures were down 66 points, or 0.1%. S&P 500 futures hovered around the flatline alongside Nasdaq-100 futures. Sigma Lithium Corporation up 6%; SanDisk Corp. up 4%; Trump Media & Technology up 3%.
Sidus Space Inc. rose 31% premarket after soaring 33% in the previous trading day.
Gold and silver stocks jumped in premarket trading on Friday.
AGQ up 7%; Coeur Mining, First Majestic Silver, Pan American Silver up 3%; Equinox Gold rose 2%; Newmont rose 1%.
Crypto stocks jumped in premarket trading on Friday.
Canaan rose 2%; CleanSpark, IREN rose 1%.
02 Key News
Nvidia, Joining Big Tech Deal Spree, to License Groq Technology, Hire Executives
NVIDIA has agreed to license chip technology from startup Groq and hire away its CEO, a veteran of Alphabet's Google, Groq said in a blog post on Wednesday.
The deal follows a familiar pattern in recent years where the world's biggest technology firms pay large sums in deals with promising startups to take their technology and talent but stop short of formally acquiring the target.
Silver Tops $75 as Gold, Platinum Extend Record Run
Silver smashed through the $75 mark for the first time on Friday, with gold and platinum also rising to all-time highs, as bets on U.S. rate cuts and geopolitical jitters fueled investor demand.
Spot gold rose 0.7% to $4,509 per ounce, after touching a record $4,530.60 earlier, while U.S. gold futures for February delivery climbed 0.8% to $4,538.
Biohaven Defended Despite Depression Trial Setback
Biohaven (BHVN) shares fell ~16% in the premarket on Friday, even as Wall Street analysts defended the biotech in reaction to its Christmas Eve announcement regarding a failure in a Phase 2 trial for its experimental depression therapy BHV-7000.
The New Haven, Connecticut-based company said on Wednesday that it will not conduct any additional psychiatric clinical trials as part of a portfolio shakeup after BHV-7000 (opakalim) missed the main goal in a Phase 2 proof-of-concept study for major depressive disorder.
Sources: Reuters, Dow Jones and Tiger Newspress, public market data
Disclaimer: For informational purposes only; not investment advice.
